China to cut prices of expensive patent drugs
Updated: 2016-05-20 17:37
(Xinhua)
|
|||||||||
BEIJING - China's health authority on Friday announced cuts of over 50 percent in the prices of three patent drugs.
The National Health and Family Planning Commission said through pharmaceutical manufacturers have agreed to lower some drugs' prices on condition of bulk purchase.
GlaxoSmithCline (GSK) will reduce the price of Tenofovir Disoprox, a treatment for hepatitis B, from 1500 yuan ($229) to 490 yuan per month.
Icotinib, an anti-cancer drug made by China's Betta Pharmaceuticals, will be dropped from 12,000 yuan to 5,500 yuan for a month's supply.
AstraZeneca will lower the monthly cost for the anti-cancer Gefitinib from 15,000 yuan to 7,000 yuan.
High prices of imported and patent drugs are a great burden for Chinese patients and the country as a whole.
Related Stories
Drug firms face industrywide probe by price regulator 2016-05-07 08:33
Drug for chronic hepatitis B to begin mass production in Qingdao facility 2016-04-13 08:01
Chinese drug regulator vows to fix vaccine distribution loopholes 2016-03-23 17:13
Cancer drug developed in China licensed by US firm 2016-03-23 14:43
Trials of cancer drug show potential 2014-09-29 07:36
Today's Top News
Still learning
EgyptAir denies finding wreckage of missing flight
China urges US to halt close surveillance
Debris found in sea in search for missing MS804
LinkedIn matches refugees with jobs
Top legislator foresees bright future for SAR
UN climate talks resume to write 'rule book'
Internet regulations: From the US to Australia
Hot Topics
Lunar probe , China growth forecasts, Emission rules get tougher, China seen through 'colored lens', International board,
Editor's Picks
|
|
|
|
|
|